Fecal microbiota transplantation for treating ulcerative colitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of fecal microbiota transplantation (FMT) as a treatment for patients with moderate to severe ulcerative colitis. The study involves infusing a fecal suspension from healthy donors into the intestines of participants to restore a healthy gut microbiome. Patients will receive FMT at least twice, with follow-up assessments conducted over a minimum of three months to evaluate the treatment's efficacy and safety. The trial is conducted at Guangzhou First People's Hospital, where a standardized microbiota isolation process is employed.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Active, moderate to severe severity (Mayo score more than 6)
* Safety using history of 5-ASA
* Able to undergo endoscopy examination

Exclusion Criteria:

* Antibiotic using in 7 days
* High risk of toxic megacolon
* Colon cancer or neoplasia in pathophysiology
* Other severe diseases (eg: cardiovascular, respiratory, gastroenteral and kidney diseases)

Where it's running

• Guangzhou First People's Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Yuqiang Nie, MD — Guangzhou First People's Hospital
• Study coordinator: Hongli Huang, MM
• Email: honglisums@126.com
• Phone: 86-13631316718

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy

  This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.

  Recruiting at 5 sites Austin Health · Hobart and 6 other locations · NCT07916727

• A Probiotic Approach to Modulating Gut Microbiota in Mild-to-Moderate Ulcerative Colitis

  A specific probiotic given rectally will be tested in adults with mild-to-moderate ulcerative colitis to see if it can help manage symptoms.

  Recruiting Catholic University of the Sacred Heart · Roma, RM · NCT07724990

• Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults

  This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.

  Recruiting at 66 sites Phase 2 AbbVie · Dothan, Alabama and 65 other locations · NCT07697456

• Fecal transplant plus standard therapy for refractory hepatic encephalopathy after TIPS

  This study tests whether adding fecal microbiota transplantation to usual medicines helps people with recurrent hepatic encephalopathy after TIPS implant.

  Recruiting Early Phase 1 Air Force Military Medical University, China · Xi'an · NCT07683936

• Longitudinal Immunophenotyping of People with Inflammatory Bowel Disease

  This study will follow adults with Crohn's disease or ulcerative colitis (and some healthy relatives) over three years to see how their immune cells change over time and how genetics and diet relate to their disease.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619547

• High Protein, High Fiber Diet for Ulcerative Colitis

  This study tests a high-protein, high-fiber diet to see if it helps people with ulcerative colitis by meeting protein needs and lowering harmful hydrogen sulfide production in the gut.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07520461

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.